Dr Allan Pamba is CEO of The Nairobi Hospital and a member of the International Hospital Federation (IHF) Governing Council. He is a Medical Doctor with a Master’s degree in Public Health from The London School of Hygiene & Tropical Medicine and business experience from the Pharmaceutical sector. Since his appointment to the CEO role in March 2020, he has led the hospital’s response to the COVID 19 Pandemic. Significantly, he has forged a Partnership between the Hospital and United Nations to build a 150 Bed stand-alone COVID hospital that will serve Kenyans and UN employees & families across Africa.
Dr Pamba built his career in the Pharmaceutical sector. He joined GSK in November 2005 as a Research Physician and rose to the position of Vice President, Global Health. He was instrumental in shaping GSK’s refreshed Global Health strategy, including prioritization of long term Global Health investments.
Dr Pamba has built a broad based experience profile spanning R&D, Commercial and Government Affairs. He began his career with GSK in R&D, leading programs that contributed to development of the first malaria vaccine as well as the most progressive treatment for Vivax Malaria to date, Tafenoquine. In a subsequent role leading GSK’s Health Partnership Initiatives, Dr Pamba led efforts that resulted in an eclectic mix of partnerships across sectors including GSK-Vodaphone, GSK-Save The Children, GSK-Barclays & GSK-Comic Relief -all focused on driving access to healthcare in developing countries. He also led GSK’s strategy for the Access to Medicines Index (ATMI) league table over a six-year period. During this period, GSK delivered 3 consecutive number 1 positions across the entire Pharmaceutical industry. In a subsequent role, Dr Pamba was Vice-President & General Manager of GSKs pharmaceuticals business across E Africa as well as Government Affairs across Africa. The focus was sustainable delivery of pharmaceuticals via innovative business models. He delivered business growth hand in hand with public health impact. Most significantly, he inspired and negotiated new vaccine introductions e.g. introduction of the Rotavirus vaccine in Rwanda, Uganda and the DRC, impacting the lives of millions of children for decades to come.
In 2013, Dr Pamba was elected to Co-Chair the UN, Every Woman Every Child Innovation Working Group (IWG) over 3 years, alongside Dr Peter Singer of Grand Challenges Canada. The Innovation Working Group (IWG) was created in 2010 to tap into the potential of innovations that can accelerate progress towards the health MDGs, in support of the Global Strategy for Women’s and Children’s Health. It was part of the UN Secretary General’s Every Woman Every Child (EWEC) initiative.
Prior to GSK, Dr Pamba trained & worked as a physician in Kenya. He worked in clinical care at various levels of health delivery including Government service, rural mission hospitals & research hospitals. He conducted clinical trials on management of severe Malaria in children at the Wellcome-Trust Research Unit in Kilifi Kenya and has published several papers on malaria. Dr Pamba set up one of the first HIV Comprehensive Care Clinics in Government service in Kenya benefitting from PEPFAR funding. He has a special interest in equitable access to healthcare & over-all economic & social development in countries across Africa & Asia. He is a passionate advocate for a shared value approach to business.